We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Real-Time PCR Detects Drug Resistant Tubercle Bacillus

By LabMedica International staff writers
Posted on 03 Aug 2010
A new diagnostic test identifies drug resistance genes of Mycobacterium tuberculosis (TB) in various human biological materials

The real-time polymerase chain reaction (RT-PCR) test can simultaneously detect TB and the mutations of drug resistant TB genes in sputum, aseptic and pleural fluid, blood, bone marrow aspiration, bronchial washing, fresh tissue, culture specimens (solid and liquid culture), urine and stool. More...
The test for multi-drug resistant TB (MDR-TB) is completed within four hours.

Healthcare workers will be able to determine quickly whether or not a patient is infected with a strain of TB that is resistant to first line drugs such as isoniazid (INH) and rifampin (Rif). The Anyplex MDR-TB is a real-time detection test of M. tuberculosis that quickly and comprehensively determines the levels of targets in a patient's various sample types, and identifies mutations of drug resistant genes, which will aid physicians to make the correct diagnostic choices.

The Anyplex MDR-TB test is manufactured by Seegene (Rockville, MD, USA). The test can detect the mutations of drug resistant genes to Rif (rpoB: D516V/Y, H526D/Y, S531L) and INH (katG: S315T (2 cases); inhA promoter: -15(C/T)). The unprecedented speed and accuracy of the Anyplex MDR-TB Tests will enable doctors and clinicians to provide quickly an appropriate treatment to prevent the spread of MDR-TB.

Current TB test methods based on culture and microscopy are hindered by speed, low sensitivity, and low specificity. Furthermore, none of these approaches are able to identify rapidly and efficiently a patient's resistance to the major drugs for treating TB. Even if sequencing and Line Probe Assay are available to test drug resistance, the procedures are quite complicated and time-consuming.

The World Health Organization (WHO; Geneva, Switzerland), reported that TB strains that are resistant to all major anti-TB drugs have been documented in every country by the nongovernmental organization recent survey. A particularly dangerous form of drug-resistant TB is MDR-TB, caused by TB bacilli resistant to the most powerful anti-TB drugs. The rate for successful MDR-TB treatment is extremely low and the progress of the disease is faster than normal TB, resulting in 40% - 50% of mortality rate.

Jong-Yoon Chun, CEO of Seegene, said, "Because MDR-TB is difficult to treat, preventing its spread throughout the population is essential. The Anyplex MDR-TB Test is a powerful new tool that healthcare workers can use to rapidly determine such infections, which will both help stop it from spreading and allow health care professionals to set a course of alternative medications for infected patients."

Related Links:
Seegene
WHO


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.